Nasopharyngitis, Pipeline Review, H1 2020 – Charleston Laboratories Inc, Pfizer Inc & Sanotize Research and Development Corp. – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Nasopharyngitis (Common Cold) – Pipeline Review, H1 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Nasopharyngitis (Common Cold) – Pipeline Review, H1 2020, provides an overview of the Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders) pipeline landscape.

Nasopharyngitis also known as common cold is an infectious, inflammatory condition that affects the throat and nasal passages. The virus can spread through droplets in the air when someone who is sick coughs, sneezes or talks. Symptoms include sore throat, runny nose, sneezing, fatigue, headache and loss of appetite. Risk factors include age and weakened immune system. Treatment includes pain relievers and decongestant medications.

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Nasopharyngitis (Common Cold) – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Nasopharyngitis (Common Cold) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 3, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from a proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders).
• The pipeline guide reviews pipeline therapeutics for Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders)

Reasons to buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered:

• Introduction
• Report Coverage
• Nasopharyngitis (Common Cold) – Overview
• Nasopharyngitis (Common Cold) – Therapeutics Development
• Pipeline Overview
• Pipeline by Companies
• Pipeline by Universities/Institutes
• Products under Development by Companies
• Products under Development by Universities/Institutes
• Nasopharyngitis (Common Cold) – Therapeutics Assessment
• Assessment by Target
• Assessment by Mechanism of Action
• Assessment by Route of Administration
• Assessment by Molecule Type
• Nasopharyngitis (Common Cold) – Companies Involved in Therapeutics Development
• Charleston Laboratories Inc
• Firebrick Pharma Pty Ltd
• Karo Pharma AB
• Orbis Biosciences Inc
• Pfizer Inc
• Sanotize Research And Development Corp
• Tris Pharma Inc
• Nasopharyngitis (Common Cold) – Drug Profiles
• Antibodies to Target TRIM-21 for Gastrointestinal and Ear Nose Throat Disorders – Drug Profile
• guaifenesin ER – Drug Profile
• Nasopharyngitis (Common Cold) – Dormant Projects
• Nasopharyngitis (Common Cold) – Discontinued Products
• Nasopharyngitis (Common Cold) – Product Development Milestones
• Featured News & Press Releases
• Appendix
• Methodology
• Coverage
• Secondary Research
• Primary Research
• Expert Panel Validation
• Contact Us
• Disclaimer

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/ikjbag

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900